No Data
INNOVENT BIO: 2024 INTERIM REPORT
Innovent Bio (01801.HK): The National Medical Products Administration has accepted the new drug application for Picozumab treating psoriasis with Silver.
Gelonghui September 26th, Innovent Bio (01801.HK) announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has officially accepted the new drug application (NDA) for Kanciqibaidankang injection (recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody, research and development code: IBI112) for the treatment of moderate to severe plaque psoriasis. This NDA acceptance is based on a Phase III registration clinical study CLEAR-1 (NCT0564) conducted in Chinese patients with moderate to severe plaque psoriasis.
Express News | Innovent Biologics - National Medical Products Administration Accepted New Drug Application for Picankibart for Moderate to Severe Plaque Psoriasis
The concept of innovative drugs is generally rising. Akeso (09926) rose by 3.78%. Institutions point out that the investment and financing environment in the pharmaceutical industry is expected to recover rapidly.
Jingu Finance News | The concept of innovative drugs is generally rising, with Akeso (09926) up 3.78%, Zai Lab (09688) up 3.38%, Asymchem Laboratories (06855) up 3.11%, Innovent Bio (01801) up 3.02%, Sinopharm (01099) up 2.78%, Junshi Bio (01877) up 2.15%, Wuxi Bio (02269) up 1.71%, Beigene (06160) up 0.8%. CSC Securities released a research report stating that with the Federal Reserve announcing its first rate cut since March 2020, global liquidity
[Hong Kong Stock Connect] Innovent Bio (01801) fell by 4%, previously subjected to a 15.5361 million shareholding reduction by Morgan Stanley.
Golden Finance News | Innovent Bio (01801) stock price is weak, with a sharper decline in the afternoon. As of the time of writing, it is trading at HKD 42.05, down 4%, with a turnover of HKD 0.357 billion. According to the documents disclosed by the Hong Kong Stock Exchange on September 17, JPMorgan Chase & Co. sold a total of 15.5361 million ordinary shares of Innovent Bio at an average on-exchange price of HKD 43.0477 per share and an average off-exchange price of HKD 42.9027 per share, totaling approximately HKD 0.669 billion. After the sale, JPMorgan Chase's latest holding is 87.8056 million shares.
Express News | Innovent Announces Clinical Data of Ibi363 (First-in-Class Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) Combined With Bevacizumab in Advanced Colorectal Cancer at the 2024 Esmo Congress
No Data
No Data
